Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model

Annals of Clinical and Laboratory Science

Volumn 33, Issue 2, 2003, Pages 192-199

  Bauer, Andrew J ^a   Patel, Aneeta ^a   Terrell, Richard ^a   Doniparthi, Krishna ^a   Saji, Motoyasu ^b   Ringel, Matthew ^b   Tuttle, R Michael ^c   Francis, Gary L ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Papillary thyroid carcinoma; Thyroid cancer; Vascular endothelial growth factor

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; THYROID CARCINOMA; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICE, NUDE; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 0038460022     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Samuel AM, Sharma SM. Differentiated thyroid carcinomas in children and adolescents. Cancer 1991;67:2186-2190.
2. Ceccarelli C, Pacini F, Lippi F, Elisei R, Arganini M, Miccoli P, Pinchera A. Thyroid cancer in children and adolescents. Surgery 1988;104:1143-1148.
3. Harness JK, Thompson NW, McLeod MK, Pasieka JL, Fukuuchi. A Differentiated thyroid carcinoma in children and adolescents. World J Surg 1992;16:547-553; discussion 553-554.
4. Schlumberger M, De Vathaire F, Travagli JP, Vassal G, Lemerle J, Parmentier C, Tubiana M. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987;6:1088-1094.
5. Welch-Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL. Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol 1998;49:619-628.
6. Fassina AS, Rupolo M, Pelizzo MR, Casara D. Thyroid cancer in children and adolescents. Tumori 1994;80:257-262.
7. LaQuaglia M, Black T, Holcomb G, Sklar C, Azizkhan R, Haase G, Newman K. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. J Pediatr Surg 2000;35:955-959.
8. Gorlin JB, Sallan SE. Thyroid cancer in childhood. Endocrinol Metab Clin North Am 1990;19:649-662.
9. McClellan DR, Francis GL. Thyroid cancer in children, pregnant women, and patients with Graves' disease. Endocrinol Metab Clin North Am 1996;25:27-48.
10. Maxon HR. The role of radioiodine in the treatment of childhood thyroid cancer - a dosimetric approach. In: Treatment of Thyroid Cancer in Childhood (Robbins JM, Ed), NIDDK, National Institutes of Health, Bethesda, MD, 1992; pp 109-126.
11. Wartofsky L. An approach to the management of patients with scan-negative, thyroglobulin-positive, differentiated thyroid cancer: alternative imaging procedures. In: Thyroid Cancer: A Comprehensive Guide to Clinical Management (Wartofsky L, Ed). Humana Press, Totowa NJ, 2000; vol 1, pp 251-262.
12. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275-288.
13. Ambrus JL, Ambrus CM, Forgach P, Stadler S, Halpern J, Sayyid S, Niswander P, Toumbis C. Studies on tumor induced angiogenesis. Exs 1992;61:436-444.
14. Bernsen HJ, van der Kogel AJ, van Daal WA, Rijken PE Vascularization and perfusion of tumors as target in cancer therapy. Ned Tijdschr Geneeskd 1997;141:364-368.
15. Bollag W. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25-dihydrox-vitamin D3 and analogs. J Cell Biochem 1994;56:427-435.
16. Bunn PA, Jr., Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest 2000;117(Suppl 1):163S-168S.
17. Folkman J Tumor angiogensis: role in regulation of tumor growth. Symp Soc Dev Biol 1974;30:43-52.
18. Huang SM, Lee JC, Wu TJ, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 2001;25:302-306.
19. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000;166:475-480.
20. Thorgeirsson UP, Lindsay CK, Cottam DW, Gomez DE. Tumor invasion, proteolysis, and angiogenesis. J neurooncol 1994;18:89-103.
21. Twardowski P, Gradishar WJ. Clinical trials of antiangiogenic agents. Curr Opin Oncol 1997;9:584-589.
22. Chiarugi V, Magnelli L, Chiarugi A, Gallo O. Hypoxia induces pivotal tumor angiogenesis control factors including p53, vascular endothelial growth factor and the NFkappaB-dependent inducible nitric oxide synthase and cyclooxygenase-2. J Cancer Res Clin Oncol 1999;125:525-528.
23. Dachs GU, Coralli C, Hart SL, Tozer GM. Gene delivery to hypoxic cells in vitro. Br J Cancer 2000;83:662-667.
24. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
25. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle PM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000;10:349-357.
26. Gordon MS, Margolin K, Talpaz M, Sledge GW, Jr., Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
27. Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 1999;27:14-21.
28. Wang G, Dong Z, Xu G, Yang Z, Shou C, Wang N, Liu T. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol 1998;124:615-620.
29. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 2000;128:1059-1066.
30. Bauer AJ TR, Doninparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD,Francis GL. Vascular endothelial growth factor monoclonal antibody (VEGF-MAb) inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 2002;12:953-961.
31. Kang YH, Kim KS, Yu YK, Lim SC, Kim YC, Park KO. The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer. J Korean Med Sci 2001;16:417-423.
32. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predict outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000;89:51-62.
33. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001;61:2256-2260.
34. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, Loening S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000;45:216-224.
35. Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC. The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer. J Urol 2001;165:2075-2081.
36. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
37. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
38. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.